Novo Nordisk A/S

詳細情報 Novo Nordisk A/S 企業名

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

企業情報

企業コードNVO

会社名Novo Nordisk A/S

上場日May 17, 1974

設立日1931

最高経営責任者「CEO」Mr. Lars Fruergaard Joergensen

従業員数76302

証券種類Ordinary Share

決算期末May 17

本社所在地Novo Alle 1

都市BAGSVAERD

証券取引所The Toronto Stock Exchange

国Denmark

郵便番号2880

電話番号4544448888

ウェブサイトhttps://www.novonordisk.com/

企業コードNVO

上場日May 17, 1974

設立日1931

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Jacob Martin Wiborg Rode

Head of Investor Relations

--

Ms. Thilde Hummel Bogebjerg

Executive Vice President - Quality, IT & Environmental Affairs

--

Mr. Helge Lund

Independent Chairman of the Board

--

Mr. David Moore

Executive Vice President - US Operations and Business Development

--

Mr. Karsten Munk Knudsen

Chief Financial Officer, Executive Vice President

--

Mr. Thomas Rantzau

Director, Employee Representative

--

Ms. Tania Sabroe

Executive Vice President - Global People, Organisation and Communication

--

Dr. Martin Holst Lange

Executive Vice President - Development

--

Mr. Andreas Fibig

Independent Director

--

Dr. Sylvie L. Gregoire, Pharm.D.

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Jacob Martin Wiborg Rode

Head of Investor Relations

--

Ms. Thilde Hummel Bogebjerg

Executive Vice President - Quality, IT & Environmental Affairs

--

Mr. Helge Lund

Independent Chairman of the Board

--

Mr. David Moore

Executive Vice President - US Operations and Business Development

--

Mr. Karsten Munk Knudsen

Chief Financial Officer, Executive Vice President

--

Mr. Thomas Rantzau

Director, Employee Representative

--

収益内訳

通貨: USD更新時刻: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

事業別USD

会社名

収益

比率

Total GLP-1

21.63B

51.35%

Obesity (Saxenda®)

9.45B

22.43%

Long-acting insulin

2.77B

6.58%

Fast-acting insulin

2.69B

6.38%

Rare blood disorders

1.76B

4.18%

Other

3.83B

9.08%

地域別USD

会社名

収益

比率

USA

24.28B

57.64%

EMEA

8.76B

20.80%

Rest of World

4.83B

11.48%

Region China

2.68B

6.37%

Canada

1.56B

3.71%

事業別

地域別

事業別USD

会社名

収益

比率

Total GLP-1

21.63B

51.35%

Obesity (Saxenda®)

9.45B

22.43%

Long-acting insulin

2.77B

6.58%

Fast-acting insulin

2.69B

6.38%

Rare blood disorders

1.76B

4.18%

Other

3.83B

9.08%

株主

更新時刻: Sat, May 17

株主統計

種類

株主統計

比率

Jennison Associates LLC

0.56%

Loomis, Sayles & Company, L.P.

0.37%

Fisher Investments

0.35%

Fayez Sarofim & Co.

0.33%

Folketrygdfondet

0.28%

Other

98.10%

株主統計

比率

Jennison Associates LLC

0.56%

Loomis, Sayles & Company, L.P.

0.37%

Fisher Investments

0.35%

Fayez Sarofim & Co.

0.33%

Folketrygdfondet

0.28%

Other

98.10%

種類

株主統計

比率

Investment Advisor

4.81%

Investment Advisor/Hedge Fund

2.79%

Research Firm

0.80%

Hedge Fund

0.78%

Pension Fund

0.29%

Insurance Company

0.20%

Bank and Trust

0.17%

Family Office

0.02%

Family Office

0.02%

Other

90.13%

機関投資家保有株

更新時刻: Thu, Feb 20

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q1

2719

350.88M

10.43%

+4.04M

2024Q4

2676

348.53M

10.35%

+330.19K

2024Q3

2529

339.29M

10.15%

-6.04M

2024Q2

2456

341.24M

10.21%

+6.87M

2024Q1

2291

330.25M

9.75%

+10.89M

2023Q4

2037

314.57M

9.30%

+1.47M

2023Q3

1826

307.14M

8.91%

+4.22M

2023Q2

1692

293.83M

8.50%

+768.69K

2023Q1

1603

284.38M

8.30%

-15.92M

2022Q4

1498

293.73M

8.57%

+2.21M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Jennison Associates LLC

19.94M

0.59%

-251.15K

-1.24%

Dec 31, 2024

Loomis, Sayles & Company, L.P.

11.57M

0.34%

+2.95M

+34.18%

Dec 31, 2024

Fisher Investments

12.64M

0.38%

-664.99K

-5.00%

Dec 31, 2024

Fayez Sarofim & Co.

11.38M

0.34%

-832.64K

-6.82%

Dec 31, 2024

Folketrygdfondet

8.90M

0.26%

+40.31K

+0.45%

Dec 31, 2024

Capital International Investors

6.75M

0.2%

-204.59K

-2.94%

Dec 31, 2024

Fidelity Management & Research Company LLC

9.89M

0.29%

-7.78M

-44.05%

Dec 31, 2024

Managed Account Advisors LLC

9.39M

0.28%

+1.11M

+13.43%

Dec 31, 2024

Renaissance Technologies LLC

8.31M

0.25%

+123.68K

+1.51%

Dec 31, 2024

詳細を見る

67.340USD

Novo Nordisk A/S

67.340

概要

企業名